- Home
- INBX vs SGP Comparison
INBX vs SGP Comparison
Compare INBX & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBX | SGP |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 932.9M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | INBX | SGP |
|---|---|---|
| Price | $81.43 | $24.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $150.00 | $45.00 |
| AVG Volume (30 Days) | ★ 220.4K | 78.4K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $10.90 | $20.15 |
| 52 Week High | $94.57 | $30.56 |
Technical Indicators
Market Signals| Indicator | INBX | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 51.16 |
| Support Level | $71.31 | $20.60 |
| Resistance Level | $85.97 | $28.17 |
| Average True Range (ATR) | 5.48 | 1.91 |
| MACD | 2.29 | 0.37 |
| Stochastic Oscillator | 71.98 | 63.32 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.